We love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye ...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.
Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.
Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka
Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous
Free AI-powered recaps of Cell & Gene: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.